Press Release

ArTara Agrees to Combine With Proteon

Transaction to create Nasdaq-listed rare and specialty disease therapeutic company
September 27, 2019

San Diego – September 27, 2019 – Cooley advised ArTara Therapeutics on its definitive agreement to merge with a wholly-owned subsidiary of Proteon Therapeutics in an all-stock transaction. Rama Padmanabhan, Karen Deschaine, Ryan Sansom, Ro Park and Lindsey Crump led the Cooley team representing ArTara.

The combined company will focus on advancing ArTara’s pipeline of transformative late-stage, de-risked rare and specialty diseases assets. It is expected to operate under the name ArTara Therapeutics and the parties have applied for the combined company to trade on the Nasdaq Capital Market under the symbol “TARA.”

In addition to the merger, Cooley advised ArTara on a concurrent $42.5 million financing led by a syndicate of healthcare dedicated investors who have entered into a stock purchase agreement to invest in the combined company. This financing will help fund the development of ArTara’s lead assets TARA-002 and IV Choline Chloride and is expected to be consummated concurrently with the closing of the merger transaction.

 “We are excited about the opportunity for this merger, which will allow ArTara to help fill the void in treatment options for these two rare diseases and potentially address additional significant unmet need in other disease areas,” said Jesse Shefferman, CEO of ArTara, in a news release.

ArTara is a rare and specialty diseases therapeutics company focused on optimizing product candidates for patients suffering from diseases where there is a significant unmet need.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 1,000+ lawyers across 15 offices in the United States, Asia and Europe.


This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.